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Abstract
Myotoxin II is a group II Lys49 phospholipase A2 (PLA2) isolated from the venom of the snake Bothrops asper. Previous
studies on a synthetic peptide derived from its heparin-binding, cationic/hydrophobic sequence 115^129 demonstrated a
direct functional role of this particular region in the in vitro cytolytic and bactericidal actions of the protein. Nevertheless, no
significant myonecrosis has been observed after local intramuscular injection of peptide 115-129 (p115-129) in mice. Since the
membrane-damaging action of p115-129 was proposed to depend on its amphiphilic character, the present study examined
the effects of substituting its cluster of three tyrosine residues by tryptophan residues, on its toxic/pharmacological activities
in vitro and in vivo. This substitution resulted in a drastic enhancement of the membrane-damaging activities of the peptide
(p115-W3), together with the clear expression of myotoxic activity in vivo. Both the heparin-binding and antigenic
characteristics of p115-129 were essentially conserved in p115-W3, suggesting that the modification did not lead to radical
structural alterations. In addition to myotoxicity, cytotoxicity, and bactericidal action, p115-W3 exerted edema-forming
activity in the mouse footpad assay. Thus, the synthetic 13-mer p115-W3 reproduced all the known toxic effects of myotoxin
II. In spite of its potent membrane-damaging actions, p115-W3 did not acquire direct hemolytic activity upon mouse
erythrocytes, an effect which is not present in myotoxin II, but that has been ascribed to the presence of tryptophan in other
cationic, membrane-damaging peptides such as mellitin from bee venom. The myotoxic activity of p115-W3 herein described
constitutes the first example of a short, PLA2-based linear synthetic peptide with the ability to reproduce this effect of a
parent protein in vivo. This finding is in clear support of the proposed relevance of the C-terminal region 115^129 in all the
membrane-damaging mechanisms exerted by myotoxin II, including the myotoxic mechanism. ß 1999 Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Phospholipases A2 (PLA2s; EC 3.1.1.4) are abun-
dant components of snake venom secretions that
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may display a diversity of toxic/pharmacological ac-
tions [1]. Among these stands myotoxicity, which
contributes to the digestion of the muscle mass of
the snake’s preys, or causes signi¢cant skeletal
muscle necrosis in accidentally envenomed humans
[2]. Myotoxic PLA2s from snake venoms have been
classi¢ed as group I (from elapids) or group II (from
viperids/crotalids) on the basis of their primary struc-
ture [3]. It was recently suggested that acquisition of
myotoxic activity by these two groups of PLA2s
might have been a convergent evolutive process [4].
The molecular basis of the myotoxic activity of
PLA2s is still unclear. Despite the common morpho-
logical pattern of muscle necrosis induced by group I
and group II myotoxic PLA2s (see reviews in [2,5,6]),
in vitro studies have provided evidence for the exist-
ence of distinct mechanisms of action. For example,
while in vitro cytolytic activity is a common charac-
teristic of all group II myotoxic PLA2s tested to date,
it was shown that notexin, a potent group I myotoxic
PLA2 from Notechis scutatus scutatus, completely
lacks cytolytic e¡ect under identical conditions
[7,8]. Therefore, structure-function considerations
concerning myotoxic PLA2s cannot be extrapolated
across group I and group II proteins.
The group II PLA2 myotoxins have been further
divided into two general categories: Asp49 and
Lys49 variants. The latter proteins are considered
PLA2 homologues, since they lack (or may possess
extremely low) catalytic activity on conventional sub-
strates [9,10]. Nevertheless, they exert myotoxic and
membrane-damaging actions comparable to the for-
mer [11^14], providing a useful model to study the
catalytic-independent mechanism of muscle damage
and to identify the key structural determinants of
this activity.
Myotoxin II is a highly basic, dimeric Lys49 PLA2
isolated from the venom of Bothrops asper [12,15,16].
The identi¢cation of structural determinants of its
toxic action is being pursued (reviewed in [6,17]). A
heparin-binding, cationic/hydrophobic region com-
prising residues 115^129 (numbering according to
[18]) of this protein was demonstrated to be involved
in its cytolytic mechanism in vitro: its corresponding
13-mer synthetic peptide 115-129 lysed endothelial
cells, albeit with a markedly lower e⁄ciency than
the protein [19]. Subsequent work reported the bac-
tericidal activity of both myotoxin II and its peptide
115-129, revealing the ¢rst catalytic-independent bac-
tericidal mechanism for a secreted PLA2 [20]. The
relevance of region 115^129 in the muscle-damaging
action of myotoxin II has been supported by dem-
onstrating that antibodies against peptide 115-129
reduce the myonecrosis induced by this protein
[17,21]. Nevertheless, a direct myotoxic e¡ect of pep-
tide 115-129 in vivo has not been observed, suggest-
ing that additional structural determinants of the
protein might be required for the full expression of
myotoxicity [17,22].
The damaging action of peptide 115-129 on mem-
branes was proposed to depend on its amphiphilic
character [19]. This 13-mer peptide displays a prom-
inent hydrophobic cluster containing three tyrosines,
surrounded by several positively charged lysine/argi-
nine side chains [15]. Consequently, while the cati-
onic residues might establish electrostatic interac-
tions with (yet unidenti¢ed) membrane constituents,
the hydrophobic residues might disturb phospholipid
bilayer integrity, initiating a rapid cell death process
[17]. In order to test this model, it was hypothesized
that substitution of the tyrosine residues by the more
hydrophobic amino acid tryptophan (hydropathy in-
dexes of 31.3 and 30.9, respectively [23]), without
altering the charge pattern, might in£uence the mem-
brane-damaging action of this peptide. The aim of
this study was to examine the consequences of the
tyrosine to tryptophan substitution on the in vitro
and in vivo toxic/pharmacological activities of pep-
tide 115-129 from myotoxin II.
2. Materials and methods
2.1. Synthetic peptides
Two 13-mer peptides, with native endings, were
synthesized using Fmoc strategy [24]. Peptide p115-
129 (numbering system of [18]) corresponds to resi-
dues 105^117 (KKYRYYLKPLCKK) of myotoxin
II [15]. Peptide p115-W3 corresponds to a triple ty-
rosine to tryptophan substitution of the former
(KKWRWWLKPLCKK). Purity of the peptides
was 94.2% and 98.5%, respectively, as assessed by
RP-HPLC on a C-18 column, and mass spectrometry
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analyses. The measured molecular masses of p115-
129 and p115-W3 were 1730.8 and 1799.5 Da, re-
spectively, corresponding to the expected values
(1730 and 1799 Da). Peptides were dissolved at the
required concentrations in 0.12 M NaCl, 40 mM
sodium phosphate (PBS), pH 7.2, prior to determin-
ing their biological activities.
2.2. Immunochemical cross-reactivity
Cross-recognition of p115-W3 by antibodies
against p115-129 was evaluated by enzyme immuno-
assay, as described [17]. Microplates were coated by
incubating 0.4 Wg of each peptide/100 Wl/well in
0.1 M Tris, 0.15 M NaCl, pH 9.0, overnight at
room temperature. The binding of rabbit anti-p115-
129 was detected with an alkaline phosphatase con-
jugate of anti-rabbit immunoglobulins (Sigma) and
p-nitrophenyl phosphate. Normal rabbit serum was
assayed in parallel against each peptide, as a control.
Absorbances were recorded on a Dynatech MR5000
reader.
2.3. Heparin-binding activity
Heparin with low a⁄nity for antithrombin [25]
was added in gradual increments to a cuvette con-
taining 200 Wg of p115-W3 (approx. 55 WM), in 2 ml
of 0.05 M Tris-HCl, 0.01 KCl, pH 7.0 bu¡er. Ab-
sorbance changes due to turbidity were monitored at
340 nm, allowing 1 min of incubation after each
heparin addition [19].
2.4. Myotoxic activity
Groups of four Swiss mice (18^20 g body weight)
received an intramuscular injection of varying
amounts of p115-W3, in 100 Wl of PBS, in their right
gastrocnemius. Control mice received an injection of
100 Wl of PBS. At di¡erent time points, blood was
collected from the tail into heparinized capillary
tubes, and the plasma creatine kinase (CK; EC
2.7.3.2) activity was determined (kit No. 520, Sigma).
CK activity was expressed in U/ml, 1 unit resulting in
the phosphorylation of 1 nmole of creatine per min
at 25‡C. Injected muscle samples were obtained after
24 h, ¢xed in Karnovsky’s solution and processed as
described [26] for histological analysis.
2.5. Edema-forming activity
Groups of four mice (24^26 g) received a subcuta-
neous injection of either p115-W3 (25 Wg) in 100 Wl
of PBS, or 100 Wl of PBS alone, in their right foot-
pad. Edema was estimated by the increase in thick-
ness of the injected footpad, which was measured
with a low-pressure spring caliper at di¡erent time
intervals [27].
2.6. Cytotoxic activity
The cytolytic e¡ect of p115-W3 was determined
using the murine endothelial cell line tEnd as a tar-
get, under identical conditions as described previ-
ously for p115-129 [7,19]. Cells were grown in 96-
well plates in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum
(FCS), 2 mM glutamine, 1 mM pyruvic acid, peni-
cillin (100 U/ml), streptomycin (0.1 mg/ml), and am-
photericin B (0.25 Wg/ml), in a humidi¢ed atmos-
phere with 7% CO2, at 37‡C, until reaching near
con£uence. After aspirating their growth medium,
di¡erent amounts of p115-W3 diluted in assay me-
dium (DMEM with 1% FCS) were added to the cul-
tures, in a volume of 150 Wl/well. After 3 h at 37‡C,
lactic dehydrogenase (LDH) activity released from
damaged cells to supernatants was determined (Sig-
ma No. 500). Controls for 0% and 100% toxicity
consisted of assay medium, and 0.1% Triton X-100
in assay medium, respectively [7].
2.7. Hemolytic activity
Washed mouse erythrocytes were prepared from
citrated blood, and resuspended at approx. 2% (v/
v) in PBS. Di¡erent amounts of p115-W3, in 50 Wl,
were added to 250 Wl of the red cell suspension, and
incubated at 37‡C. After 30 min, 2 ml of PBS were
added, and the release of hemoglobin was estimated
by determining the absorbance of supernatants at
540 nm. PBS alone or 0.1% Triton X-100 were uti-
lized, respectively, to establish the 0 and 100% refer-
ence values.
2.8. Bactericidal activity
Escherichia coli (ATCC 29648) was utilized as a
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target for determining bactericidal activity, by incu-
bating 4U105 cells with varying amounts of p115-
W3, for 20 min at 37‡C, in PBS containing 1% pep-
tone. Surviving bacteria were counted by the dilution
plate technique, as described [20].
2.9. Intravenous and intraperitoneal lethal activity
Groups of three mice (16^18 g) received either an
intravenous or an intraperitoneal injection of p115-
W3 (100 Wg) in 0.2 ml of PBS. Deaths were recorded
during the following 48 h.
3. Results
3.1. Antigenic and heparin-binding properties of
p115-W3
Rabbit antibodies raised against p115-129 showed
a signi¢cant cross-reactivity with p115-W3, as deter-
mined by the enzyme immunoassay titration curves
(Fig. 1), resulting in a binding signal of 60^70% rel-
ative to the homologous antigen. On the other hand,
the heparin-binding activity of p115-W3 in solution
was evidenced by the rapid formation of insoluble
complexes, which caused maximal turbidity at a hep-
arin/peptide molar ratio of 0.10^0.15 (Fig. 2). Fur-
ther additions of heparin gradually reversed the
turbidity, showing the reversibility of complex for-
mation at di¡erent heparin/peptide ratios, with resol-
ubilization of complexes at heparin excess (Fig. 2).
3.2. In vivo activities of p115-W3
Intramuscular injection of p115-W3 in mice re-
sulted in a dose-dependent increase of plasma crea-
tine kinase activity (Fig. 3A), which peaked by 1 h
(Fig. 3B). Macroscopically, mice showed some di⁄-
culty in mobilizing the injected limb, which appeared
moderately swollen, after a few minutes. Histological
observation of injected muscle sections revealed areas
containing numerous necrotic, hypercontracted
myo¢bers with a clumped appearance (not shown).
No signs of hemorrhage or other alterations were
observed microscopically in the injected muscle tis-
sue.
Subcutaneous injection of p115-W3 in the footpad
of mice induced an immediate edema response,
reaching a peak in the ¢rst 30 min, and gradually
returning to basal levels by 6 h (Fig. 4).
Injection of up to 100 Wg of p115-W3 (6 Wg/g body
weight) by either intravenous or intraperitoneal
routes in mice did not result in death, or in any
Fig. 1. Antibodies to peptide 115-129 cross-react with peptide
115-W3 by enzyme immunoassay. Di¡erent dilutions of rabbit
antiserum to p115-129 (¢lled symbols) or normal rabbit serum
(empty symbols) were added to microwells containing 0.4 Wg of
either p115-129 (F,E) or p115-W3 (b,a). Bound antibodies
were detected by an anti-rabbit IgG/alkaline phosphatase conju-
gate, as described in Section 2. Each point represents the
mean þ S.D. of triplicate wells.
Fig. 2. Peptide 115-W3 forms macromolecular complexes with
heparin in solution. Heparin was added in gradual increments
to a cuvette containing 200 Wg of p115-W3 (approx. 55 WM), in
2 ml of 0.05 M Tris-HCl, 0.01 KCl, pH 7.0 bu¡er. Turbidity
was monitored at 340 nm, allowing 1 min of incubation after
each heparin addition.
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evident alterations, during the following 48 h. Plasma
creatine kinase levels after the intravenous or intra-
peritoneal injection of p115-W3 in these animals re-
mained unaltered (data not shown).
3.3. In vitro activities of p115-W3
p115-W3 displayed cytolytic activity upon endo-
thelial cells, in the concentration range of 30^50
WM (Fig. 5). This potency is approx. 15-fold higher
than that reported for p115-129, under identical as-
say conditions [19]. The cytolytic e¡ect of p115-W3
was completely neutralized when this peptide was
pre-incubated with heparin at a 1:1 molar ratio
(Fig. 5). On the other hand, p115-W3 did not cause
lysis of mouse erythrocytes, over the same concen-
tration range utilized in the cytotoxicity assay (data
not shown).
Incubation of p115-W3 with E. coli 29648 at
37‡C resulted in signi¢cant bacterial killing, in the
Fig. 3. Myotoxic activity of peptide 115-W3 in mice. (A) Di¡er-
ent doses of p115-W3 were injected by intramuscular route in
the right gastrocnemius of mice (18^20 g body weight) in a vol-
ume of 100 Wl. Control mice received an injection of 100 Wl of
PBS. After 3 h, plasma creatine kinase (CK) activity was deter-
mined. (B) A ¢xed dose of p115-W3 (200 Wg) was injected as
described and the plasma CK activity was determined at the in-
dicated time points. Each point represents the mean þ S.D. of
four animals.
Fig. 4. Edema-forming activity of peptide 115-W3 in the mouse
footpad assay. A ¢xed dose (25 Wg) of p115-W3 in 100 Wl of
PBS (b) was injected subcutaneously in the footpads of mice
(24^26 g body weight). Control mice received 100 Wl of PBS
alone (a). At the indicated time points, the increase in footpad
thickness was determined as described in Section 2. Each point
represents the mean þ S.D. of four animals.
Fig. 5. Cytotoxic activity of peptide 115-W3 on murine endo-
thelial cells in vitro, and its neutralization by heparin. Di¡erent
amounts of p115-W3 (b) were added to tEnd endothelial cells
growing in 96-well microplates, in a total of 150 Wl (10 Wg/well
corresponding to approx. 35 WM of p115-W3). After 3 h of in-
cubation at 37‡C, cell culture supernatants were assayed for lac-
tic dehydrogenase (LDH) activity, as an estimator of cytolysis.
Medium alone or with 0.1% Triton X-100 was utilized as 0 and
100% reference values, respectively. Each point represents the
mean þ S.D. of triplicates. To determine neutralization, cells
were challenged with 480 Wg of p115-W3 previously incubated
for 15 min at 37‡C with heparin (F), at a 1:1 molar ratio.
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0.1^1 WM range of concentrations (Fig. 6). The bac-
tericidal activity of p115-W3 was at least 10-fold
higher, in comparison to that of p115-129 (Fig. 6).
4. Discussion
The structural basis of the myotoxic action of
Lys49 PLA2s has begun to emerge in recent years.
Neutralization studies on B. asper myotoxin II based
on the use of heparin ¢rst highlighted the functional
relevance of its region 115^129 [19]. Synthetic p115-
129 reproduced the in vitro cytolytic [19] and bacter-
icidal [20] actions of myotoxin II, although not its
myotoxic activity in vivo (B. Lomonte, unpublished
data). Since the action of peptide 115-129 on mem-
branes is assumed to be dependent on its amphiphilic
character [19], provided by the combination of cati-
onic and hydrophobic residues, this study examined
the e¡ects of replacing the cluster of three tyrosine
residues of p115-129 by tryptophan, a more hydro-
phobic amino acid. Results demonstrated that this
substitution drastically enhances the membrane-dam-
aging activities of the peptide. Both the antigenic and
heparin-binding characteristics of p115-129 were es-
sentially conserved in p115-W3, indirectly suggesting
that the TyrCTrp substitution did not lead to rad-
ical structural alterations, although this would have
to be con¢rmed by direct analyses.
Interestingly, p115-W3 displayed a clear myotoxic
activity in mice, as demonstrated by direct histolog-
ical evaluation of injected muscle tissue, as well as by
the dose-dependent increment in plasma creatine ki-
nase activity. To the best of our knowledge, the my-
otoxic activity of p115-W3 herein described consti-
tutes the ¢rst report of a PLA2-based linear synthetic
peptide with the ability to reproduce this e¡ect of a
parent protein in vivo. This ¢nding is in clear sup-
port of the proposed role of region 115^129 as a
determinant of the membrane-damaging mechanisms
exerted by myotoxin II, including myotoxicity [6,17].
Other authors have suggested that, since the cationic/
hydrophobic region 115^129 of Lys49 PLA2s is not
present in some neurotoxic/myotoxic Asp49 PLA2s
(i.e., crotoxin), it may not be essential for myotox-
icity [28,29]. However, di¡erent types of PLA2s may
exert myotoxicity by diverse mechanisms [4,7,8], and
major functional di¡erences may exist even between
the Asp49 and Lys49 PLA2 variants [30]. In the case
of the Lys49 PLA2 myotoxin II, the present results
agree with a key functional role of region 115^129 in
myotoxicity, without excluding the participation of
other protein determinants.
The observed enhancement of the membrane-dam-
aging activities of p115-W3 demonstrates the impor-
tant role of hydrophobic residues in its toxic mech-
anism. While maintaining the same positively
charged residues of p115-129, the TyrCTrp substi-
tution of p115-W3 would favor hydrophobic interac-
tions with phospholipid bilayers, leading to its in-
creased toxic potencies. Tryptophan is known to be
critically involved in the interaction of proteins with
membranes [31,32]. Previous work reported the rele-
vance of Trp110 in the lethal/neurotoxic action, but
not in the enzymatic activity of the group I PLA2
notexin [33]. The 115^129 region of a basic, myotoxic
Asp49 PLA2 from Agkistrodon piscivorus piscivorus
[34] contains a natural TyrCTrp substitution at po-
sition 119, compared to myotoxin II. In mellitin, a
small cationic peptide from bee venom, it was dem-
onstrated that the single Trp19 is essential for its
membrane-damaging activity upon erythrocytes
[35,36]. Noteworthily, in spite of its clear mem-
brane-damaging activities, p115-W3 did not display
hemolytic activity, even at concentrations causing
complete cytolysis of cultured endothelial cells. In
this regard p115-W3 resembled myotoxin II, which
Fig. 6. Bactericidal activity of peptide 115-W3 on E. coli, com-
pared to peptide 115-129. Varying amounts of p115-W3 (F) or
p115-129 (b) were incubated with 4U105 E. coli (ATCC 29648)
for 20 min at 37‡C. Surviving bacteria were counted by the di-
lution plate technique. Each point represents the mean þ S.D. of
four replicas.
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lacks hemolytic activity, despite being cytolytic to a
broad range of cell types [7]. Thus, while the
TyrCTrp substitution in p115-W3 drastically en-
hanced its membrane-damaging activities, it did not
result in the acquisition of properties unrelated to
those of its parent protein, such as hemolytic activity.
The edema-forming activity displayed by Asp49
PLA2s has generally been attributed to their enzy-
matic activity [37,38], but several Lys49 PLA2s can
also induce this e¡ect [12,39,40], probably by causing
a direct degranulation of mast cells [39^41]. The ede-
ma-forming activity observed for p115-W3 is in
agreement with the notion that Lys49 PLA2s induce
edema independently of an intrinsic catalytic activity.
Moreover, results suggest that edema might be in-
duced by the same structural motifs of the protein
involved in myotoxicity, since p115-W3 was both
myotoxic and edematogenic.
The basis for the selectivity of myotoxin II to-
wards skeletal muscle ¢bers in vivo [6] as well as
the nature of its membrane ‘acceptor site’ are still
unknown. Since p115-W3 a¡ected both eukaryotic
membranes (causing myonecrosis in vivo or cytolysis
in vitro), and prokaryotic membranes (being bacter-
icidal to E. coli), it would be di⁄cult to envisage that
its myotoxic mechanism involves the interaction with
speci¢c proteic receptors for PLA2s on skeletal
muscle. This does not exclude the possibility that
myotoxin II might utilize other protein region(s) to
selectively target to such receptors, although no evi-
dence along this line has yet been reported for the
group II myotoxic PLA2s. The general damaging ac-
tivity of p115-W3 suggests that it interacts with es-
sential membrane components which should be com-
mon to both eukaryotes and prokaryotes, possibly
phospholipids or glycolipids. Previous studies, based
on the construction of bacterial chimeras, demon-
strated the interaction of myotoxin II and p115-129
with lipopolysaccharide moieties of Gram-negative
bacteria [20].
The bactericidal action of p115-129 [20] was en-
hanced by at least one order of magnitude in p115-
W3, which was e¡ective in the 0.1^1 WM concentra-
tion range. In view of the small size (13-mer) of
p115-W3 in comparison to other bactericidal cationic
peptides, its e⁄cient activity is worthy of notice as a
possible lead compound for the development of nov-
el antimicrobial agents.
In conclusion, the TyrCTrp substitution of p115-
129 markedly enhanced its membrane-damaging ef-
fects, demonstrating that it is possible to reproduce
all the known toxic activities of B. asper myotoxin II,
including its in vivo myotoxic e¡ect, with only 13
amino acid residues. Indirectly, these ¢ndings stress
the importance of region 115^129 as a major struc-
tural determinant of the toxic activities of myotoxin
II, and possibly of related Lys49 PLA2 myotoxins
present in many crotalid snake venoms.
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